Education
About Us
Working with TipRanks
Follow Us
Tivic Health Systems (TIVC)
NASDAQ:TIVC
TIVC Stock Chart & Stats
$1.38
>-$0.01(-2.18%)
At close: 4:00 PM EST
$1.38
>-$0.01(-2.18%)
Day’s Range― - ―
52-Week Range$1.00 - $15.65
Previous CloseN/A
Volume226.20K
Average Volume (3M)99.84K
Market Cap
$2.78M
Enterprise Value-$2.33M
Total Cash (Recent Filing)$3.45M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.97
Shares Outstanding2,525,778
10 Day Avg. Volume91,463
30 Day Avg. Volume99,839
Financial Highlights & Ratios
PEG Ratio3.37
Price to Book (P/B)667.70
Price to Sales (P/S)2170.01
P/FCF Ratio-295.65
Enterprise Value/Market Cap-0.84
Enterprise Value/Revenue-4.84
Enterprise Value/Gross Profit8.34
Enterprise Value/Ebitda0.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Government Engagement And BARDA InterestSustained government engagement and BARDA/DoD interest create a structural commercialization pathway for Entolimod as a medical countermeasure. Agency evaluation and potential stockpile procurement provide durable non-dilutive funding, de-risking development and offering a large, repeatable customer.
In-house Manufacturing And CDMO Revenue PotentialOwning manufacturing capability improves control of supply, shortens timelines, and can lower COGS long-term. Velocity Bioworks also enables revenue diversification via CDMO services to other biotechs, creating a structural second revenue stream that can stabilize cash flow beyond product sales.
Improved Gross Margins (ex-reserve)Material gross margin improvement indicates the core product and manufacturing economics can be attractive once operational issues are resolved. Sustained mid-to-high gross margins support potential path to profitability as revenue scales or higher-margin biopharma programs advance.
Bears Say
High Cash Burn And Weak Cash GenerationPersistent negative operating and free cash flow (~-$6.1M TTM) means the company requires ongoing external financing to fund development and operations. This reduces strategic optionality, pressures timing of trials/manufacturing scale-up, and increases dependency on capital markets or partners over the medium term.
Very Small Revenue Base And Persistent LossesWith minimal revenue and sustained negative margins, the core business has not demonstrated scalable commercial traction. The wind-down of ClearUP further reduces near-term product sales, meaning the company must rely on successful biopharma pivots or external funding to achieve sustainable revenues.
Acquisition Financing Raises Leverage And Dilution RiskFinancing the Scorpius asset purchase with sizable debt and preferred convertible equity materially increases leverage and potential dilution. This complicates capital structure, elevates fixed obligations or conversion risk, and may constrain future financings or shareholder value if development timelines slip.
Tivic Health Systems News
TIVC FAQ
What was Tivic Health Systems’s price range in the past 12 months?
Tivic Health Systems lowest stock price was $1.00 and its highest was $15.65 in the past 12 months.
What is Tivic Health Systems’s market cap?
Tivic Health Systems’s market cap is $2.78M.
When is Tivic Health Systems’s upcoming earnings report date?
Tivic Health Systems’s upcoming earnings report date is Apr 01, 2026 which is in 55 days.
How were Tivic Health Systems’s earnings last quarter?
Tivic Health Systems released its earnings results on Nov 14, 2025. The company reported -$1.966 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.966.
Is Tivic Health Systems overvalued?
According to Wall Street analysts Tivic Health Systems’s price is currently Overvalued.
Does Tivic Health Systems pay dividends?
Tivic Health Systems does not currently pay dividends.
What is Tivic Health Systems’s EPS estimate?
Tivic Health Systems’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tivic Health Systems have?
Tivic Health Systems has 2,525,778 shares outstanding.
What happened to Tivic Health Systems’s price movement after its last earnings report?
Tivic Health Systems reported an EPS of -$1.966 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -21.466%.
Which hedge fund is a major shareholder of Tivic Health Systems?
Currently, no hedge funds are holding shares in TIVC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tivic Health Systems
Tivic Health Systems Inc. operates as a bioelectronic device company that delivers non-invasive neuromodulation products for the treatment of inflammatory conditions. Its primary product is ClearUP, is a medical device intended to relieve sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, including BestBuy.com and FSAStore.com. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.
TIVC Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Tivic Health demonstrated substantial progress in its strategic transformation and development of Entolimod, improving its financial position despite experiencing increased net loss and manufacturing delays.View all TIVC earnings summariesTechnical Analysis
Ownership Overview
1.31% Insiders
0.28% Mutual Funds
7.68% Other Institutional Investors
90.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---